Arthur C. Ley, Ph.D., is a Consultant with BioProcess Technology Consultants. Dr. Ley has over 25 years of experience with a proven track record in the process development efforts needed to advance biotherapeutics from concept to market.
From 2004 to 2012, he served as Vice President Process Sciences at Dyax, where he led the growth of the new Process Sciences Department to develop, deliver, and optimize the processes, analytical methods, and formulations for smooth and rapid transfer of new products into both clinical and commercial manufacturing environments. Under Dr. Ley’s leadership, Dyax streamlined downstream process development and created a dedicated formulations and analytical group to support ongoing product development. He was a major contributor to Dyax’s successful BLA and MAA submissions for its flagship product Kalbitor, providing subject matter expertise on drug substance and drug product and effectively responding to regulatory agency questions.
Previously at Dyax, he was the Director and Vice President of Research and in these roles he directed the use of phage display technology to discover and develop the company’s proprietary lead peptides, small proteins, and antibodies and oversaw the establishment of the in-house cell culture facility.
As a Senior Research Scientist at Protein Engineering Corp., Dr. Ley was intimately involved in the discovery and development of the proprietary company phage display and DNA binding protein technologies.
Dr. Ley’s academic experience includes positions as Assistant and Adjunct Professor at The Rockefeller University and Visiting Research Professor at Harvard University, where he performed and directed research programs into the biophysics and molecular biology of energy transfer and conversion in photosynthesis.
Dr. Ley holds a Ph.D. from the University of California, San Diego and completed post-doctoral training at UCSD and The Rockefeller University. Dr. Ley is an inventor on numerous issued US and international patents, including the original US patents for the phage display technology.